Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as α particles, β or Auger electrons, to cancer cells via a targeting vector. The discovery of new molecular targets through systems biology and other approaches has widened the scope for radiopharmaceutical development. Innovations in antibody engineering and humanisation, recombinant DNA technology, conjugation chemistry and, increasingly, nanotechnology have provided new approaches to the delivery of radionuclides to cancer cells. The increased availability of radioisotopes that have not traditionally been considered for therapy, such as α particle emitters, has also broadened the indications for targeted radiotherapy.

Original publication

DOI

10.1016/j.clon.2013.06.004

Type

Journal article

Journal

Clin Oncol (R Coll Radiol)

Publication Date

10/2013

Volume

25

Pages

604 - 609

Keywords

radioimmunotherapy, targeted radiotherapy, vectors, α Particles, β electrons, Drug Delivery Systems, Humans, Immunotoxins, Neoplasms, Radioimmunotherapy, Radiopharmaceuticals